40 results
8-K
EX-99.2
g77t5txbaljv3 s2o
3 Aug 21
Regulation FD Disclosure
4:36pm
8-K
EX-99.3
dr72eh7sbr02oubkjb
3 Aug 21
Regulation FD Disclosure
4:36pm
8-K
EX-99.1
klbre9di75rxqg am92j
3 Aug 21
Cassava Sciences Reports Second Quarter 2021 Financial Results
8:45am
8-K
EX-99.1
k5g rbx3gnir4
21 Apr 21
Cassava Sciences Reports First Quarter 2021 Financial Results and Announces Guidance on Clinical Data Release
8:45am
8-K
EX-10.1
qx7m6vb8io1
11 Mar 21
Cassava Sciences Announces Pharmaceutical Supply Agreement for Simufilam
4:59pm
8-K
EX-99.1
bczvwsvv6ea39c10p46
8 Feb 21
Regulation FD Disclosure
4:09pm
8-K
EX-99.2
0yq49yba
8 Feb 21
Regulation FD Disclosure
4:09pm
8-K
EX-99.1
ajbbp76g0zse7 7zttt
6 Jan 21
Cassava Sciences Appoints Dr. James Kupiec as Chief Clinical Development Officer
4:39pm
8-K
EX-99.1
hehs7 7zt
14 Sep 20
Regulation FD Disclosure
4:01pm
8-K
EX-99.2
xistmxrnjrlwc
14 Sep 20
Regulation FD Disclosure
4:01pm
8-K
EX-99.1
636a2skrop2dn4m9
12 Aug 20
Cassava Sciences Announces Second Quarter 2020 Financial Results and Mid-year Business Review
8:30am
8-K
EX-99.2
inrnj167dbyeuew
3 Jun 20
Regulation FD Disclosure
5:29pm
8-K
EX-99.1
6sny7m2t8nou g3m
15 May 20
Top-line Results from a Phase 2b Study of PTI-125 in Alzheimer’s Disease Does Not Meet Primary Endpoint
8:20am